Real-world data favor dimethyl fumarate, fingolimod for MS

VANCOUVER – Dimethyl fumarate and fingolimod appear to have an edge over other disease-modifying therapies for multiple sclerosis (MS) in real-world practice, according to a comparative effectiveness...
Source: Family Practice News - Category: Primary Care Source Type: news